Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2023-10-09 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the board's approval of the share buyback, the intended use of funds, and the status update that no shares have been repurchased as of the specified date. It references regulatory rules about share repurchases and the obligation to disclose progress. The document is short (624 characters) and focuses on the update of the share buyback activity, not a full financial report or other types of filings. Therefore, it fits the category of Transaction in Own Shares (POS).
2023-10-09 Chinese
关于在研产品注册受理相关情况的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company regarding the acceptance of a registration application for a drug product by the national drug regulatory authority. It details the product, regulatory approvals, and potential risks but does not contain financial statements or detailed financial data. The document is short (876 characters) and serves as an update on regulatory progress rather than a financial report or detailed filing. It is not an annual or interim report, earnings release, or management discussion. It is an official regulatory announcement about product registration and related approvals, fitting best under Regulatory Filings (RNS).
2023-09-28 Chinese
关于在下属子公司之间调剂担保额度及为全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the adjustment and provision of guarantee limits between subsidiaries of the company, including specifics about guarantee contracts, approval by the board and shareholders, financial data of the guaranteed subsidiary, and compliance with regulatory requirements. It is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is also not related to changes in management, voting results, or legal proceedings. The content focuses on financing guarantees and credit arrangements within the group, which fits the category of Capital/Financing Update (CAP). The document length is 3551 characters, which is sufficient for a substantive announcement but not a full financial report. Therefore, the classification is Capital/Financing Update (CAP) with high confidence.
2023-09-22 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 95% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the board's approval of the share buyback, the intended use of funds, and the status of the repurchase as of a certain date. It references previous announcements about the repurchase plan and states that the company has not yet started repurchasing shares. The content is focused on the update of the share buyback activity rather than the initial announcement or a full report. This fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares. The document length is short and it is not a full financial report or an announcement of a report publication, so it is not RPA or RNS. Therefore, the correct classification is POS with high confidence.
2023-09-01 Chinese
回购报告书
Transaction in Own Shares Classification · 95% confidence The document is titled as a "回购报告书" which translates to "Share Repurchase Report" or "Buyback Report." It details the company's plan to repurchase its own shares using self-owned funds, including the purpose, amount, price limits, implementation period, and regulatory compliance. It also includes risk disclosures, board approvals, and procedural authorizations related to the share buyback. The document is comprehensive and contains substantive information about the share repurchase plan, not just an announcement of the plan or a brief summary. This matches the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares. The document length (7761 characters) and detailed content confirm it is the report itself, not merely an announcement or certification. Therefore, the correct classification is POS with high confidence.
2023-09-01 Chinese
关于回购股份事项前十名股东及前十名无限售条件股东持股信息的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the shareholding information of the top ten shareholders and top ten unrestricted shareholders prior to a share repurchase plan approved by the company's board. It includes detailed shareholding percentages and names of shareholders as of a specific date. The document references a share repurchase (buyback) plan but does not contain financial statements or earnings data. It is not a full financial report, earnings release, or management discussion. It is specifically about the company's own shares and their ownership status in relation to a repurchase. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is short and focused on shareholding data related to a buyback, confirming the classification.
2023-09-01 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.